Adisease-modifying drug Ximena Sarinana would revolutionize the

Adisease-modifying drug clarifies cuento ximena sarinana lyrics would revolutionize ximena sariñana retells the treatment of this debilitatingdisease."TNF alpha is a cytokine and a key player in inflammation, and has beenidentified as a major contributor to pain (signs and symptoms) and cartilagedegeneration (structure modification), the main clinical characteristics ofOA. Current treatments for OA comprise mainly of non-steroidalanti-inflammatory drugs and intra-articular injections of hyaluronic acids andcorticosteroids. These treatments, however, are restricted to pain management,but do not address cartilage degeneration. Blocking TNF alpha offers theopportunity to attack both aspects, managing pain and structure modification.Because of the degenerative nature of OA, every year more than 130,000 kneereplacement surgeries are performed in the U.S alone Similar numbers areseen in Europe and other major markets.

Peter Lichtlen, M.D., Ph.D., Head of Clinical Development at ESBATech AG,added, "Antibody fragments have a number of advantages over whole antibodies,resulting from their smaller molecular weight normal ximena sarinana lyrics . In fact, they are capable ofpenetrating tissues not accessible to conventional monoclonal antibodies, suchas avascularized tissues like cartilage jimena sarinana . By delivering high amounts of ESBA105directly to the affected joint, the antibody fragment quickly and efficientlydistributes to the relevant sites in the joint ximena sarinana letras . On the other hand, based onthe local delivery and the short systemic half life, systemic exposure ofESBA105 is very low as compared to traditional TNF alpha inhibitors ximena sarañana .

This is acrucial point in OA, which is a non-life-threatening, rather local disease.Therefore, systemic suppression of TNF alpha, as achieved by marketed TNFalpha inhibitors and associated with various safety issues, is not justifiedfor osteoarthritis patients . The molecular properties of ESBA105 are tailoredto the needs of patients suffering from local disease ximena cuento . In this initialclinical trial, we will focus on safety and effects on signs and symptoms.However, the ultimate goal for ESBA105 in OA is disease modification."About OsteoarthritisOA is a clinical syndrome of severe joint pain and dysfunction associated withjoint degeneration, in particular cartilage loss ximena . More than 70 million peoplein the seven major pharmaceutical markets and 40 million in the U.S . alone areafflicted with OA.The disease occurs more frequently with age and recentdata show the OA market to be growing by three percent annually At this ratethe U.S. patient population will grow to 60 million by 2020.About ESBATech's antibody fragment platform technologyESBATech is the first and only company to date that has successfully screenedand characterized the entire human pool (1.5 million) of naturally occurringvariable immunoglobulin (VH and VL) domains to select highly stable, solubleand monomeric single-chain antibody fragment frameworks. ESBATech's unique,scientific approach to stabilize monomeric, single-chain antibody fragments(scFvs) using its proprietary fully-human antibody fragment frameworks haselucidated the drug-like properties of these proprietary scFvs.